HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) Antibody

Product Graph
383.5€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx224338
tested applications
ELISA, WB, IHC, IF/ICC

Description

HLA-DRA Antibody is a Mouse Monoclonal against HLA-DRA.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA)
Host
Mouse
Reactivity
Human
Recommended Dilution
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000, IF/ICC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Isotype
IgG1
Purification
Purified from ascites by Protein G chromatography.
Size 1
100 µl
Form
Liquid
Tested Applications
ELISA, WB, IHC, IF/ICC
Buffer
PBS, containing 0.05% sodium azide.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P13645
Gene ID
3858
OMIM
113800
Background
Antibody anti-HLA-DRA
Status
RUO
Note
Concentration: 1 mg/ml -

Descripción

Related Products

EH4749

Human anti-HLA-DRA antibody ELISA Kit

Ver Producto
EH9136

Human HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) ELISA Kit

Ver Producto
FNab03906

HLA-DRA antibody

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells(APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules(heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP(class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells(DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Ver Producto